Loading stock…

Vertex Pharmaceuticals Incorporated (VRTX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Vertex Pharmaceuticals Incorporated

VRTXMarket cap $128BPrice $505.6

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops and sells medicines for rare genetic diseases that affect fewer than 200,000 Americans each. Their cystic fibrosis drugs cost $300,000+ per year but can transform patients' lives completely.

In Bastion Portfolios?

52W Return+21%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+10%7

Revenue Forecast

Rev CAGR (1y)+10%6

Rev CAGR (3y)+11%7

Rev CAGR (5y)+11%8

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+10%7

EPS Growth Y+3+15%7

Quality

Margins

EBIT Margin39%9

Net Income Margin35%9

Free Cash Flow Margin30%9

Debt

Net Debt/EBITDA-2.210

Efficiency

ROE24%8

ROA17%10

Earnings Stability66

GEAR+VERY STRONG94

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)243

P/E Ratio (Forward 3y)222

P/BV6.33

EV Multiples

EV/EBITDA Fwd202

EV/EBIT Fwd204

Yield

Free Cash Flow Yield3.0%5

Dividend Yieldna–

Momentum

Short term

1 month return-4%5

3 month return+1%7

YTD return+12%7

Mid term

Price vs 52wHigh90%8

1 year return+20%7

Long term

3 year return+40%5

5 year return+183%9

Risk Shield

Price Risk

Beta0.58

Volatility28%7

Free Cash Flow

Free Cash Flow Margin30%9

Free Cash Flow Yield3.0%5

Quality

ROCE23%9

Earnings Stability66

Net Debt/EBITDA-2.210

02Growth

Is it actually growing, and how fast?

VRTXVertex Pharmaceuticals

Revenue FY25$11.0B

GROWTH RATING↗

STRONG68 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+11%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+10%7

EPS growth, FY28E+15%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 68% of companies worldwide.

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 11%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 10%/yr over the last 3 years and is set to keep growing around 11%/yr.

The runway holds up: revenue is set to grow 11%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 11%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return+1%7

YTD return+12%7

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+20%7

3-year return+40%5

5-year return+183%9

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +40% over three years and +183% over five, ahead of 60% of the market.

It's up 20% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+1%) and so far this year (+12%).

WATCH

Returns sit at the market level over the past month (-4%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Vertex. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

VRTXVertex Pharmaceuticals

Revenue FY25$11.0B

GROWTH RATING↗

STRONG68 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+11%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+10%7

EPS growth, FY28E+15%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 68% of companies worldwide.

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 11%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 10%/yr over the last 3 years and is set to keep growing around 11%/yr.

The runway holds up: revenue is set to grow 11%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 11%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG72 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return+1%7

YTD return+12%7

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+20%7

3-year return+40%5

5-year return+183%9

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +40% over three years and +183% over five, ahead of 60% of the market.

It's up 20% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+1%) and so far this year (+12%).

WATCH

Returns sit at the market level over the past month (-4%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Vertex. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community